CGRYX
Price
$33.95
Change
-$0.01 (-0.03%)
Updated
Aug 6 closing price
Net Assets
746.14M
RMEBX
Price
$59.72
Change
-$0.00 (-0.00%)
Updated
Aug 6 closing price
Net Assets
108.54B
Interact to see
Advertisement

CGRYX vs RMEBX

Header iconCGRYX vs RMEBX Comparison
Open Charts CGRYX vs RMEBXBanner chart's image
Invesco Comstock Select Y
Price$33.95
Change-$0.01 (-0.03%)
VolumeN/A
Net Assets746.14M
American Funds American Mutual R2E
Price$59.72
Change-$0.00 (-0.00%)
VolumeN/A
Net Assets108.54B
CGRYX vs RMEBX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
CGRYX vs. RMEBX commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGRYX is a Hold and RMEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMEBX has more cash in the bank: 109B vs. CGRYX (746M). CGRYX pays higher dividends than RMEBX: CGRYX (1.75) vs RMEBX (1.11). CGRYX was incepted earlier than RMEBX: CGRYX (29 years) vs RMEBX (11 years). RMEBX (1.07) is less costly to investors than CGRYX (0.69). CGRYX is a more actively managed with annual turnover of: 70.00 vs. RMEBX (31.00). RMEBX has a lower initial minimum investment than CGRYX: RMEBX (250) vs CGRYX (1000). RMEBX annual gain was more profitable for investors over the last year : 10.55 vs. CGRYX (-1.66). RMEBX (53.24) and CGRYX (53.23) have equivalent 5 years return.
CGRYXRMEBXCGRYX / RMEBX
Total Expense Ratio0.681.0764%
Annual Report Gross Expense Ratio0.691.0764%
Fund Existence29 years11 years-
Gain YTD5.2379.36656%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets746M109B1%
Annual Yield % from dividends1.751.11158%
Returns for 1 year-1.6610.55-16%
Returns for 3 years3.9425.1516%
Returns for 5 years53.2353.24100%
Returns for 10 years20.0677.0726%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EXPE185.143.30
+1.81%
Expedia Group
ABUS3.470.06
+1.76%
Arbutus Biopharma Corp
LDWY5.180.08
+1.62%
Lendway
KYMR41.35-1.62
-3.77%
Kymera Therapeutics
AIXI1.63-0.07
-4.12%
XIAO-I Corporation